Thulium:YAG vapoenucleation in large volume prostates.
Identifieur interne : 000411 ( PubMed/Corpus ); précédent : 000410; suivant : 000412Thulium:YAG vapoenucleation in large volume prostates.
Auteurs : Thorsten Bach ; Christopher Netsch ; Laura Pohlmann ; Thomas R W. Herrmann ; Andreas J. GrossSource :
- The Journal of urology [ 1527-3792 ] ; 2011.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Thulium.
- methods : Prostatectomy.
- pathology : Prostatic Hyperplasia.
- surgery : Prostatic Hyperplasia.
- therapeutic use : Lasers, Solid-State.
- Aged, Aged, 80 and over, Humans, Laser Therapy, Male, Middle Aged, Organ Size.
Abstract
Tm:YAG vapoenucleation was introduced as a minimally invasive treatment in patients with benign prostatic obstruction. The efficiency and safety of Tm:YAG vapoenucleation must still be confirmed in large volume prostates to prove the size independence of this promising treatment option. We evaluated the safety and efficiency of Tm:YAG vapoenucleation in patients with a prostate volume of 80 cc or greater and benign prostatic obstruction during a 12-month followup.
DOI: 10.1016/j.juro.2011.07.073
PubMed: 22014812
Links to Exploration step
pubmed:22014812Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Thulium:YAG vapoenucleation in large volume prostates.</title><author><name sortKey="Bach, Thorsten" sort="Bach, Thorsten" uniqKey="Bach T" first="Thorsten" last="Bach">Thorsten Bach</name><affiliation><nlm:affiliation>Department of Urology, Asklepios Hospital Barmbek, Hamburg, Germany. t.bach@asklepios.com</nlm:affiliation></affiliation></author><author><name sortKey="Netsch, Christopher" sort="Netsch, Christopher" uniqKey="Netsch C" first="Christopher" last="Netsch">Christopher Netsch</name></author><author><name sortKey="Pohlmann, Laura" sort="Pohlmann, Laura" uniqKey="Pohlmann L" first="Laura" last="Pohlmann">Laura Pohlmann</name></author><author><name sortKey="Herrmann, Thomas R W" sort="Herrmann, Thomas R W" uniqKey="Herrmann T" first="Thomas R W" last="Herrmann">Thomas R W. Herrmann</name></author><author><name sortKey="Gross, Andreas J" sort="Gross, Andreas J" uniqKey="Gross A" first="Andreas J" last="Gross">Andreas J. Gross</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="doi">10.1016/j.juro.2011.07.073</idno><idno type="RBID">pubmed:22014812</idno><idno type="pmid">22014812</idno><idno type="wicri:Area/PubMed/Corpus">000411</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000411</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Thulium:YAG vapoenucleation in large volume prostates.</title><author><name sortKey="Bach, Thorsten" sort="Bach, Thorsten" uniqKey="Bach T" first="Thorsten" last="Bach">Thorsten Bach</name><affiliation><nlm:affiliation>Department of Urology, Asklepios Hospital Barmbek, Hamburg, Germany. t.bach@asklepios.com</nlm:affiliation></affiliation></author><author><name sortKey="Netsch, Christopher" sort="Netsch, Christopher" uniqKey="Netsch C" first="Christopher" last="Netsch">Christopher Netsch</name></author><author><name sortKey="Pohlmann, Laura" sort="Pohlmann, Laura" uniqKey="Pohlmann L" first="Laura" last="Pohlmann">Laura Pohlmann</name></author><author><name sortKey="Herrmann, Thomas R W" sort="Herrmann, Thomas R W" uniqKey="Herrmann T" first="Thomas R W" last="Herrmann">Thomas R W. Herrmann</name></author><author><name sortKey="Gross, Andreas J" sort="Gross, Andreas J" uniqKey="Gross A" first="Andreas J" last="Gross">Andreas J. Gross</name></author></analytic><series><title level="j">The Journal of urology</title><idno type="eISSN">1527-3792</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Humans</term><term>Laser Therapy</term><term>Lasers, Solid-State (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Organ Size</term><term>Prostatectomy (methods)</term><term>Prostatic Hyperplasia (pathology)</term><term>Prostatic Hyperplasia (surgery)</term><term>Thulium (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Thulium</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Prostatectomy</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Prostatic Hyperplasia</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Prostatic Hyperplasia</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Lasers, Solid-State</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Humans</term><term>Laser Therapy</term><term>Male</term><term>Middle Aged</term><term>Organ Size</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Tm:YAG vapoenucleation was introduced as a minimally invasive treatment in patients with benign prostatic obstruction. The efficiency and safety of Tm:YAG vapoenucleation must still be confirmed in large volume prostates to prove the size independence of this promising treatment option. We evaluated the safety and efficiency of Tm:YAG vapoenucleation in patients with a prostate volume of 80 cc or greater and benign prostatic obstruction during a 12-month followup.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">22014812</PMID><DateCreated><Year>2011</Year><Month>11</Month><Day>14</Day></DateCreated><DateCompleted><Year>2012</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-3792</ISSN><JournalIssue CitedMedium="Internet"><Volume>186</Volume><Issue>6</Issue><PubDate><Year>2011</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Journal of urology</Title><ISOAbbreviation>J. Urol.</ISOAbbreviation></Journal><ArticleTitle>Thulium:YAG vapoenucleation in large volume prostates.</ArticleTitle><Pagination><MedlinePgn>2323-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.juro.2011.07.073</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Tm:YAG vapoenucleation was introduced as a minimally invasive treatment in patients with benign prostatic obstruction. The efficiency and safety of Tm:YAG vapoenucleation must still be confirmed in large volume prostates to prove the size independence of this promising treatment option. We evaluated the safety and efficiency of Tm:YAG vapoenucleation in patients with a prostate volume of 80 cc or greater and benign prostatic obstruction during a 12-month followup.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Included in this trial were 90 consecutive patients undergoing 90 W Tm:YAG vapoenucleation. Vapoenucleation was done using the 2 μm continuous wave Tm:YAG laser combined with a mechanical tissue morcellator. We analyzed patient demographic, perioperative and 12-month followup data. Complications were assessed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Mean preoperative prostate volume was 108.6 cc (range 80 to 200), mean International Prostate Symptom Score was 23.5 (range 8 to 35) and mean quality of life score was 4.3 (range 1 to 6). There was an 86% reduction (range 67% to 99%) in prostate volume on transrectal ultrasound by 12 months and an 88% decrease (range 58% to 100%) in prostate specific antigen. International Index of Erectile Function score remained stable. Peak urinary flow rate, International Prostate Symptom Score and quality of life improved significantly (p <0.001), as did post-void residual urine. The overall complication rate was manageable. Two patients required blood transfusion and 10 experienced early postoperative stress incontinence. During followup 7% of patients had symptomatic urinary tract infection and 2 had persistent grade I stress urinary incontinence. The reoperation rate due to urethral stricture was 1.8% during the 12-month followup.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Tm:YAG vapoenucleation is a safe, effective and size independent treatment option for benign prostatic obstruction. As shown by reductions in transrectal ultrasound prostate volume and prostate specific antigen, complete removal of the adenoma can be achieved by this procedure.</AbstractText><CopyrightInformation>Copyright © 2011 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bach</LastName><ForeName>Thorsten</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Urology, Asklepios Hospital Barmbek, Hamburg, Germany. t.bach@asklepios.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Netsch</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Pohlmann</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Herrmann</LastName><ForeName>Thomas R W</ForeName><Initials>TR</Initials></Author><Author ValidYN="Y"><LastName>Gross</LastName><ForeName>Andreas J</ForeName><Initials>AJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>10</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Urol</MedlineTA><NlmUniqueID>0376374</NlmUniqueID><ISSNLinking>0022-5347</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>8RKC5ATI4P</RegistryNumber><NameOfSubstance UI="D013932">Thulium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D053685">Laser Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D053844">Lasers, Solid-State</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009929">Organ Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011468">Prostatectomy</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011470">Prostatic Hyperplasia</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000601">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013932">Thulium</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2011</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pii">S0022-5347(11)04503-4</ArticleId><ArticleId IdType="doi">10.1016/j.juro.2011.07.073</ArticleId><ArticleId IdType="pubmed">22014812</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Terre/explor/ThuliumV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000411 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000411 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Terre
|area= ThuliumV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:22014812
|texte= Thulium:YAG vapoenucleation in large volume prostates.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:22014812" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ThuliumV1
| This area was generated with Dilib version V0.6.21. |  |